Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL
© Macdonald et al; licensee BioMed Central Ltd. 2006
Received: 03 August 2005
Accepted: 10 January 2006
Published: 10 January 2006
Pim-1, 2 and 3 are a group of enzymes related to the calcium calmodulin family of protein kinases. Over-expression of Pim-1 and Pim-2 in mice promotes the development of lymphomas, and up-regulation of Pim expression has been observed in several human cancers.
Here we show that the pim kinases are constitutively active when expressed in HEK-293 cells and are able to phosphorylate the Bcl-2 family member Bad on three residues, Ser112, Ser136 and Ser155 in vitro and in cells. In vitro mapping showed that Pim-2 predominantly phosphorylated Ser112, while Pim-1 phosphorylated Ser112, but also Ser136 and Ser155 at a reduced rate compared to Ser112. Pim-3 was found to be the least specific for Ser112, and the most effective at phosphorylating Ser136 and Ser155. Pim-3 was also able to phosphorylate other sites in Bad in vitro, including Ser170, another potential in vivo site. Mutation of Ser136 to alanine prevented the phosphorylation of Ser112 and Ser155 by Pim kinases in HEK-293 cells, suggesting that this site must be phosphorylated first in order to make the other sites accessible. Pim phosphorylation of Bad was also found to promote the 14-3-3 binding of Bad and block its association with Bcl-XL.
All three Pim kinase family members predominantly phosphorylate Bad on Ser112 and in addition are capable of phosphorylating Bad on multiple sites associated with the inhibition of the pro-apoptotic function of Bad in HEK-293 cells. This would be consistent with the proposed function of Pim kinases in promoting cell proliferation and preventing cell death.
Pim-1, 2 and 3 make up a group of closely related mammalian serine/threonine kinases that form part of the calmodulin dependent protein kinase family [1, 2]. Pim-1 was first identified as an oncogenic gene in murine T-cell lymphomas, which became activated after pro-viral insertion in the 3'UTR of the Pim-1 gene . Insertion in this region stabilised the mRNA for Pim-1 thus up-regulating the protein . Over-expression of the Pim-1 gene in B and T cells in transgenic mice resulted in a high level of lymphoma development in these mice, confirming the oncogenic properties of this protein [5, 6]. A second related gene, Pim-2, was also identified as a common site of viral insertion in murine lymphomas . Like Pim-1 the over-expression of Pim-2 in transgenic mice predisposes the mice to the development of lymphoma . The precise mechanism by which Pim-1 and 2 promote the formation of lymphomas is not fully understood, however it has been suggested that Pim-1 synergises with c-myc in this process [8–10]. Pim-1 also appears to be important in the development of human cancers, as the Pim-1 gene maps to an area showing karyotypic abnormalities in leukaemia, and the mRNA for Pim-1 has been shown to be up-regulated in prostate cancer and leukaemia [11–13]. A third isoform, Pim-3, which is 72% identical to Pim-1 also exists in mammalian cells although the oncogenic properties of this protein are less well studied. Pim-3 has recently been shown to be up-regulated in Ewing's tumour cell lines, is a transcriptional target for the oncogenic EWS transcription factors and is able to promote anchorage-independent cell growth in tissue culture models . Recently, over-expression of Pim-3 has been demonstrated in a mouse model of hepatocellular carcinoma, although the functional role of Pim-3 was not determined .
Several substrates have been suggested for Pim-1 including mdm2 , p21 , cdc25 phosphatase  and c-myb , all proteins involved in control of the cell cycle. Pim-2 has been reported to maintain phosphorylation of the translational repressor 4EBP-1 and to phosphorylate and inactivate the pro-apoptotic protein Bad on Ser112 [20, 21]. Pim-1 has also been reported to be able to phosphorylate Bad on Ser112 , however the ability of Pim-3 to phosphorylate Bad is unknown. Both Pim-1 and Pim-2 therefore appear to act as survival or proliferation signals in vivo. Consistent with this Pim-1 expression has been shown to promote cytokine independent growth of haematopoetic cells [23, 24]. In contrast, less is known about the substrates of Pim-3, and its function in vivo is still largely unclear.
Bad is a pro-apoptotic member of the BH3 family of proteins. Active Bad induces apoptosis by binding to anti-apoptotic Bcl-2 family members such as Bcl-XL. This allows other pro-apoptotic proteins such as BAX and BAK to aggregate, inducing cytochrome C release from the mitochondria and caspase activation (reviewed in ). The activity of Bad is repressed by phosphorylation, and three residues (Ser112, Ser136 and Ser155) have been identified as the predominant in vivo phosphorylation sites. In addition to Pim-2 several kinases have been identified as potential kinases for Bad, including PKB [26–28], RSK [29, 30], PAK , p70S6K  and PKA [33–35]. It seems likely that multiple kinases may phosphorylate Bad on these sites in vivo, depending on the cell type and situation. Consistent with this, several of the proposed kinases preferentially phosphorylate one or two of the three sites in Bad. For instance, in vitro RSK phosphorylates Ser112 and to a lesser extent Ser155, while PKB phosphorylates Ser136 and PKA preferentially phosphorylates Ser155 . In addition to these phosphorylation sites, an unidentified kinase has been shown to inhibit apoptosis by phosphorylating Bad on Ser170 . Conversely, phosphorylation by Cdc2 of Ser128 in Bad was found to promote the apoptotic activity of Bad .
In this paper we examine the specificity of Pim-1, 2 and 3 for the Ser112, 136 and 155 phosphorylation sites in Bad, both in vitro and in HEK-293 cells.
Pim kinases phosphorylate Bad on three sites in vitro
Phosphorylation site analysis of Bad. Phosphorylated peptides were eluted from the HPLC (Fig 2) were identified by ms/ms mass spectrometry. The amino acid numbers of the peptide in murine Bad are indicated and the phosphorylation site underlined. Results for the release of 32P during Edman degradation cycle sequencing and phospho amino acid analysis of these fractions are also indicated. The percentage of 32P obtained in each HPLC peak, relative to the total 32P eluted in all the peaks is also listed (last column)
Phospho-amino acid analysis
Solid Phase cycle no.
154 – 163
136 – 146
110 – 131
110 – 131
110 – 131
110 – 131
154 – 163
136 – 146
110 – 131
110 – 131
170 – 178
92 – 107
AAT NS HHGGAGAMETR
Thr 94 Ser 96
170 – 178
S AGT ATQMR
Ser 170 Thr 173
Pim-3 phosphorylated Bad also gave peaks corresponding to P1, P2, P3 and P4, and again these were confirmed as Ser112, Ser136 and Ser155 by ms/ms and solid phase sequencing (Fig 2C and 2D). Of the three kinases Pim-3 gave the highest phosphorylation of Ser136 and Ser155 compared to Ser112 in Bad (Table 1). Five further smaller phospho peptide peaks (P5-9) were also observed in the HPLC when Pim-3 was used to phosphorylate Bad. These sites were not however significantly phosphorylated by Pim-1 or Pim-2. P5 was observed in the flow through of the column and peptides in this fraction were not identified by mass spectrometry. Prediction from the Bad sequence shows that tryptic digest would give 2 small peptides that contain serine or threonine that could have been phosphorylated. Phosphopeptides from P9 were also not successfully identified by mass spectrometry. P7 was identified as the peptide AATNSHHGGAGAMETR (residues 92 to 107 of Bad) with 1 phospho group. Ms/ms analysis suggested that this was a mixture of phosphorylation on either Thr94 or Ser96. Solid phase sequencing confirmed this result, and also suggested that Ser96 was the predominant site (Fig 2D). P6 and P8 were identified by mass spectrometry as SAGTATQMR (residues 170 to 178 in Bad) phosphorylated at Ser170. The phosphorylation of Ser170 was confirmed by solid phase sequencing for both P6 and P8. Surprisingly, solid phase sequencing also showed that in P8 the 4th residue in the peptide was also phosphorylated, suggesting that Thr 173 may also be phosphorylated by Pim-3.
Pim kinases are constitutively active in HEK-293 cells and phosphorylate Bad on Ser112, 136 and 155
GST-Bad expressed by transient transfection of serum starved HEK-293 cells, in the absence of the co-expression of any kinase, was found to be phosphorylated on Ser136, bur not Ser112 or Ser155, as judged by immunoblotting using antibodies specific for the various phosphorylation sites. Consistent with previous studies , stimulation of the cells with PMA resulted in a modest increase in Ser112 phosphorylation whilst forskolin resulted in increases in Ser155 phosphorylation and, to a lesser extent, Ser136 (Fig 3B). Co-expression of Pim-1 and Bad resulted in increased phosphorylation of Ser136 and phosphorylation of Ser112 and Ser155, when compared to Bad expressed in the absence of Pim-1. Similar results were also obtained for co-expression of Pim-2 or Pim-3, although Pim-2 had a reduced effect on Ser136 phosphorylation in Bad compared to co-expression with Pim-1 and Pim-3 (Fig 3B). The phosphorylation of Bad by Pim kinases was not further increased by PMA stimulation, although Ser155 phosphorylation was further increased by Forskolin stimulation. The phosphorylation of Bad was dependent on the kinase activity of Pim kinases, as co-expression of kinase dead versions of Pim-1, 2 or 3 and Bad did not result in the phosphorylation of Bad (Fig 3C).
Similar effects of the mutants were also seen in the absence of co-expressed Pim-1, when cells were stimulated with agents to induce the phosphorylation of specific sites within Bad. PMA promotes Bad Ser112 phosphorylation, probably via RSK, however this was prevented by Ser136 mutation. Forskolin stimulated Ser155 phosphorylation via PKA, and this was also prevented by mutation of Ser136 [see Additional file 1].
Pim promotes 14-3-3 binding to Bad via phosphorylation of Ser136 and dissociation from Bcl-XL
Phosphorylation of a protein can create binding sites for 14-3-3 proteins, and Ser112 and 136 in Bad lie in a potential consensus 14-3-3 motif . Ser155 does not lie in a consensus 14-3-3 binding motif, however in vitro phosphorylation of Bad by PKA (which predominantly phosphorylates Ser155) does promote 14-3-3 interaction . To test the ability of Bad to interact with 14-3-3, GST-Bad was co-expressed in HEK-293 cells with Pim-1, and 14-3-3 overlay assays were used to determine if Bad could bind 14-3-3 proteins. In the overlay assay, recombinant 14-3-3 protein was used to detect the presence of proteins on a Western blot capable of binding 14-3-3. GST-Bad isolated by glutathione-Sepharose pull downs from the cell lysates was tested for its ability to bind to 14-3-3. In the absence of Pim-1 co-expression, GST-Bad was not significantly phosphorylated on Ser112, 136 or 155 and did not bind 14-3-3 in the overlay assay (Fig 4A and 4C). Co-expression of Pim-1 however resulted in phosphorylation of all three sites and promoted interaction of the GST-Bad with 14-3-3 in the overlay assay. Mutation of either Ser112 or Ser155 to alanine resulted in a modest reduction in the ability of the Pim-1 phosphorylated GST-Bad to interact with 14-3-3 proteins in the overlay assay (Fig 4C). As expected, mutation of Ser136 to alanine, which also blocks the phosphorylation of Ser112 and Ser155, completely blocked the ability of GST-Bad to interact with 14-3-3 proteins. Mutation of Ser136 to an acidic residue also blocked the ability of Bad to bind to 14-3-3 proteins in the overlay assay, even though Pim-1 was able to phosphorylate both Ser112 and Ser155 in the Ser136Asp or Ser136Glu Bad mutants (Fig 4C). These data suggest that Ser136 is the major 14-3-3 binding site. Consistent with this, a double mutant of both Ser112 and Ser155 to alanine, which was phosphorylated on Ser136 (Fig 4B), was still able to interact with 14-3-3 proteins in the overlay assay (Fig 4D). Similar to Pim-1, when Pim-2 or Pim-3 were co-expressed with GST-Bad, they were also able to promote 14-3-3 binding in the overlay assay (Fig 4E). To test if Pim kinases promoted the interaction of Bad and 14-3-3 proteins in cells, Pim kinases and GST-Bad were co-expressed in HEK-293 cells and the GST-Bad isolated by glutathione-Sepharose pull downs and blotted for the presence of endogenous 14-3-3 proteins using a pan 14-3-3 isoform antibody (Fig 4F). In the absence of Pim kinase co-expression, 14-3-3 proteins were not detected in the GST-Bad pull downs, however expression of Pim-1, 2 or 3 was found to promote the binding of 14-3-3 to GST-Bad in cells (Fig 4F). The ability of Pim kinases to promote the interaction of Bad and 14-3-3 was dependent on their kinase activity, as co-expression of kinase dead Pim-1, 2 or 3 did not promote 14-3-3 binding as judged by either co-precipitation or 14-3-3 overlay assays (Fig 4E and 4F).
Phosphorylation of Bad has been shown to prevent an interaction with Bcl-XL . The ability of Pim kinases to prevent the interaction of GST-Bad with endogenous Bcl-XL was tested in pull down experiments. HeLa cells were used for these experiments as these cells express detectable levels of endogenous Bcl-XL.
Pim-1, 2 or 3 were found to be able to phosphorylate Bad in vitro and in cells. Pim-2 was found to be the most specific of the Pim kinases for Ser112 of Bad in vitro, although it was also able to phosphorylate Ser155 both in vitro and when over-expressed in HEK-293 cells. Pim-2 was a poor Ser136 kinase in vitro and, consistent with this, was the least effective of all the Pim kinases at phosphorylating this site in cells. In agreement with this Pim-2 has previously been described to phosphorylate Ser112 [20, 21]. Interestingly, the phosphorylation of Ser136 and Ser155 by over-expression of Pim-2 has been suggested to be dependent on the cell line used . Both previous results and our results suggest this may reflect different over-expression levels of Pim-2 achieved in the different cell types used. Pim-1 was able to phosphorylate Ser112, Ser136 and Ser155 in Bad, however phosphorylation of Ser112 was significantly more efficient than phosphorylation of the other sites in vitro. Pim-1 has previously been found to phosphorylate Ser112 in Bad, although its ability to phosphorylate Bad on other sites has not previously been reported . The ability of Pim-3 to phosphorylate Bad has not previously been addressed. Here we report that Pim-3 is also able to phosphorylate Ser112 in Bad. Interestingly Pim-3 was the most effective kinase in vitro for Ser136 of Bad. Unlike Pim-1 or Pim-2, which demonstrated a marked preference for Ser112, Pim-3 was also effective at phosphorylating Ser136, and to a lesser extent Ser155, when Bad protein was used as an in vitro substrate (Table 1). In addition Pim-3 was also able to phosphorylate other sites in Bad including Ser170 in vitro. This site has been reported to be phosphorylated in vivo, although the kinase responsible was not identified in the initial study . Mutagenesis of Ser170 in Bad has suggested that phosphorylation of this site, like phosphorylation of Ser112, 136 and 155, inhibits the pro-apoptotic activity of Bad . Phosphorylation of this site by Pim-3 would therefore be consistent with the pro-survival function of Pim-3. To the best of our knowledge, this study is the first to report a Pim-3 cellular substrate.
The interaction between the phosphorylation sites in Bad and their roles in Bad function is complex. Phosphorylation of Ser136 appears to be required for the phosphorylation of Ser112 and Ser155 to occur when Bad is over-expressed in cells. Similarly, Ser136 appears to be the major 14-3-3 binding site in Bad (Fig 4) [38, 40], while Ser155 is suggested to be required for binding to Bcl-XL . Despite this, phosphorylation of endogenous Bad on Ser136 has proven hard to demonstrate in vivo. This may reflect the poor sensitivity of the antibodies available, however it has also been suggested that this site may not be physiologically important . In contrast to this, studies using transfected Bad have suggested that phosphorylation of this site is essential for the phosphorylation of Ser112 and Ser155 and 14-3-3 binding, which are required to inhibit the apoptotic activity of Bad [38, 40]. Studies on Ser112 have suggested that this site may be a 'gatekeeper' site, and that dephosphorylation of this site is required to recruit a phosphatase that then dephosphorylates Ser136 and Ser155 . An extension of this idea lead to the proposal that Pim-1 only directly phosphorylates Ser112, and that an increase in Ser136 phosphorylation when Pim-1 was over-expressed was due to a decrease in the rate of Ser136 dephosphorylation . Whilst this cannot be completely excluded, it is not consistent with our data that Pim-1 can promote the phosphorylation of a Ser112Ala Bad mutant in cells. The interplay between the different Bad phosphorylation sites is thus very complex and further work is required to completely understand these mechanisms. An added degree of complexity is the number of physiological kinases for Bad, including Pim-1-3, PKB, PAK, RSK, PKA [26–35] and possibly other kinases potentially playing a role. The exact context in which Pim phosphorylates Bad in vivo may therefore depend on both cell type and stimulus and remains to be fully understood.
The ability of Pim kinases to phosphorylate Bad is consistent with the suggested role of these kinases in pro survival or proliferation pathways. The finding that all three Pim kinases can phosphorylate similar sites in Bad could in part explain the redundancy between Pim kinases in providing a cellular survival signal. The knockout of Pim kinase might therefore be expected to have a severe phenotype, however a triple knockout of Pim-1, 2 and 3 has recently been reported. Surprisingly these mice were found to be viable, and while they were smaller in size than wild type mice they displayed no obvious health problems . These mice did however show reduced proliferation of some haematopoietic cells in response to growth factors. Interestingly, a triple knockin mutation of Bad (resulting in the mutation of Ser112, 136 and 155 to alanine) in mice was also found to be viable and did not show increased levels of apoptosis in tissues under normal conditions . These mice also displayed reduced numbers of T and B cells and reduced cytokine induced survival of these cells in vitro, a phenotype with some similarity to that of the triple Pim kinase knockout.
We present here biochemical evidence that all three isoforms of Pim kinase are able to phosphorylate Bad. The major site of Bad phosphorylation for all three isoforms of Pim kinase is Ser112. However, we also demonstrate that Pim kinases are able to phosphorylate Bad to a lesser extent on Ser136 and Ser155 in vitro. Interestingly Pim-3 exhibits less specificity for Ser112 than Pim-1 or Pim-2, and was the most effective pim isoform for Ser136 and Ser155 phosphorylation in Bad in vitro. We also provide evidence that Pim kinases may modulate the phosphorylation of Bad on Ser112, Ser136 and Ser155 in HEK-293 cells.
The coding region for an amino-terminal extended version of human Pim-1 (NCBI Acc. NM_002648) predicted to be synthesised by alternative translation initiation at an upstream CUG codon  was amplified from IMAGE consortium EST clone 4591723 using primer 5'-gcgaattcgccaccatggactacaaggacgacgatgacaagctg ccgcacgagccccacgag-3' incorporating a 5' FLAG tag sequence and primer 5'- gcgaattcctatttgctgggccccggcgac-3'. The PCR product was ligated into pCR2.1-TOPO vector (Invitrogen), sequenced, and sub-cloned as an Eco R1-Eco R1 insert into the pCMV5 expression vector . The same coding region was cloned into expression vector pEBG2T  without the 5' FLAG tag sequence using appropriate primers as a Spe 1-Spe 1 insert. The coding region for an amino-terminal extended version of human Pim-2 (NCBI Acc. NM_006875.2) predicted to be synthesised by alternative translation initiation at an upstream CUG codon was amplified from IMAGE consortium EST clone 3913552 using primer 5'- gcgaattcgccaccatggactacaaggacgacgatgacaagctg gcgcgcgcggcgaatctcaac-3' incorporating a 5' FLAG tag sequence and primer 5'- gcggatccttagggtagcaaggaccaggccaaag-3'. The PCR product was ligated into pCR2.1-TOPO vector, sequenced, and sub-cloned as an Eco R1-Bam H1 insert into the pCMV5 expression vector. The same coding region was cloned into expression vector pEBG2T without the 5' FLAG tag sequence using appropriate primers as a Bam H1-Not 1 insert. Nucleotides 125–1455 (stop codon of CDS) of murine Pim-3 (NCBI Acc. NM_145478) mRNA were amplified from IMAGE consortium EST clone 4924687 using primer 5'-gcgaattcgagcgtccggcttccccag-3' and primer 5'-gcgaattctcacttgtcatcgtcgtccttgtagtccaagctctcactgctggaagtg-3' incorporating a FLAG tag sequence at the 3' end. The PCR product was ligated into pCR2.1-TOPO vector, sequenced, and sub-cloned as an Eco R1-Eco R1 insert into expression vector pCMV5. The same region of Pim-3 mRNA was cloned (lacking the Pim-3 stop codon) with a C-terminal GST sequence (generated by overlap PCR) into pCMV5 as a Kpn1/HindIII insert. The Pim-3 sequence was also cloned with an N-terminal His Tag in to a pFastBAC vector for expression in Baculovirus expression. Kinase dead versions of the Pim-1, Pim-2 and Pim-3 expression constructs were generated by mutating the 'DFG' motif to 'AFG' in each case using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). A cDNA encoding full-length murine Bad was amplified from the pGEX Bad construct described in  using primer 5'- gcggatccatgggaaccccaaagcagccctc-3' and primer 5'- gtgcggccgctcactgggagggggtggagcc-3'. The PCR product was ligated into pCR2.1-TOPO vector, sequenced, and sub-cloned as a BamH 1-Not 1 insert into expression vector pEBG6P-1 (pEBG2T containing a PreScission Protease site). S112A, S155A, S136A, S136D and S136E mutants were generated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene).
HEK-293 cells were maintained in DMEM containing 10% FBS (Sigma), 2 mM L-glutamine, 50 units/ml penicillin G and 50 μg/ml streptomycin (Invitrogen). Cells were transfected using PEI as described . Prior to stimulation and analysis cells were starved in DMEM lacking serum for eighteen hours at 37°C and 5% CO2. Cells were stimulated with IGF (100 ng/ml 5 min), sorbitol (0.5 M for 30 min), AICar (2 mM for 1 hour), UV-C (200 Jm2/10 sec followed by 1 hour incubation at 37°C), hydrogen peroxide (1 mM for 1 hour), PMA (400 ng/ml for 15 min), anisomycin (10 μg/ml for 1 hour) or Forskolin (20 μM for 30 min). Cells were lysed in 50 mM Tris-HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 1 mM sodium pyrophosphate, 0.27 M sucrose, 1% (v/v) Triton X-100, 0.1% (v/v) 2-mercaptoethanol. Lysates were clarified at 13,000 rpm for 5 min at 4°C and the supernatants quick frozen in liquid nitrogen and stored at -80°C until used.
Peptide kinase assay
For in vitro kinase assays 1 unit of activity was defined as the amount of kinase that catalysed the phosphorylation of 1 nmol of substrate in 1 min into the peptide RSRMSSYPDRG at a 30 μM peptide concentration. To determine the ability of Pim kinases to phosphorylate peptides derived from Bad, each peptide substrate was used at the concentrations indicated and incubated with 10 mU of kinase in a 50 μl volume for 10 min at 30°C in 10 mM MgCl2 – 0.1 mM [γ32P]-ATP, 50 mM Tris-HCl, pH 7.5, 10 mM EGTA, 0.1% 2-mercaptoethanol and 2.5 μM PKI. Reactions were terminated by spotting on to p81 paper, followed by immersion in 50 mM ortho-phosphoric acid. All papers were then washed three times in 50 mM ortho-phosphoric acid to remove unincorporated ATP, once in acetone and then dried and the 32P incorporation was determined by Cerenkov counting. The peptides used were RSRMSSYPDRG (corresponding to Ser112), RGSRSAPPNL (corresponding to Ser136) and RELRRMSDEFEGS (corresponding to Ser155).
To determine the activity of Pim kinases expressed in Hek-293 cells, FLAG-Pim kinase was immunoprecipitated from 50 μg of soluble cell lysate using an anti FLAG antibody (Sigma) and assayed by standard protocols . Briefly, immunoprecipitates were washed twice in 0.5 M NaCl, 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA and 0.1% (v/v) 2-mercaptoethanol and once in 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA and 0.1% (v/v) 2-mercaptoethanol. Precipitates were then resuspended in 35 μl of reaction buffer (containing Tris/HCl pH7.5, EGTA, PKI and RSRMSSYPDRG substrate peptide,), and the reaction was started by the addition of 10 μl 50 mM MgAc, 0.5 mM [γ32P]-ATP and incubated at 30°C for 15 min. Final concentrations of reagents in the assay were 50 mM Tris/HCl pH7.5, 0.1 mM EGTA 0.1% 2-mercaptoethanol 2.5 μM PKI (an inhibitor of PKA), 30 μM substrate peptide peptide, 10 mM MgAc and 0.1 mM [γ32P]-ATP. Reactions were stopped by transfer onto P81 paper and washing in 75 mM orthophosphoric acid.
In vitro Bad phosphorylation
Human Pim-1 and Pim-2 were cloned with an N-terminal GST-tag and expressed in HEK-293 cells. Murine Pim-3 was cloned with an N-terminal His-tag and expressed in a Baculovirus expression system using Sf 9 insect cells. Murine Bad was cloned with an N-terminal GST-tag and expressed in bacteria. All recombinant proteins were purified using standard affinity chromatography techniques on glutathione or Ni-NTA sepharose as appropiate. Purified recombinant Pim-kinases (10 mU) were incubated with 2 μg of recombinant Bad over the indicated time period in 50 mM Tris-HCl, pH 7.5, 10 mM EGTA, 0.1% 2-mercaptoethanol, 2.5 μM PKI, 10 mM MgCl2 and 0.1 mM [γ32P]-ATP. Reactions were stopped by the addition of SDS loading buffer and samples analysed on a 4–12% Novex gel (Invitrogen). Protein was detected by Colloidal blue staining and the appropriate band was excised and the amount of 32P incorporation was determined by Cerencov counting.
Phosphorylation site identification
Samples were run on a 4–12% polyacrylamide gel, and the substrate band was excised and the amount of 32P incorporated determined by Cerenkov counting. For phospho site mapping, the protein was reduced with dithiothreitol, alkylated with iodoacetamide and digested with trypsin. The resulting peptides were applied to a Vydac 218TP5215 C18 column equilibrated in 0.1% trifluoroacetic acid and the column developed with a linear gradient of acetonitrile/0.1% trifluoroacetic acid at a flow rate of 0.2 ml/min while collecting 0.1 ml fractions. 32P radioactivity was recorded with an on-line monitor. Phosphorylation site mapping was performed essentially as described previously . Identification of 32P labelled peptides was performed by MALDI-TOF and MALDI-TOF-TOF mass spectrometry on an Applied Biosystems 4700 using a matrix of 10 mg/ml alpha-cyanocinnamic acid in 50% acetonitrile/0.1% trifluoroacetic acid/10 mM ammonium phosphate. Sites of phosphorylation within the peptides were determined by a combination of MALDI-TOF-TOF mass spectrometry and solid phase Edman sequencing. Solid phase sequencing was performed on an Applied Biosystems Procise 494C after coupling the peptide covalently to a Sequelon-arylamine membrane and measuring by Cerenkov counting the 32P radioactivity released after each cycle.
GST-Bad pull down
Lysates were incubated with glutathione-sepharose for 2 hours at 4°C. Immunoprecipitates were pelleted by centrifugation for 1 min at 13,000 g and washed twice in 50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.1 mM EGTA and 0.1 % 2-mercaptoethanol and once in 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA and 0.1 % 2-mercaptoethanol. Protein complexes were eluted in SDS sample buffer.
Soluble cell extract was run on 4–12% Novex gels (Invitrogen) and transferred onto nitrocellulose membranes and blotted using standard techniques. Antibodies that recognise p-Bad (Ser112), p-Bad (Ser 136), pBad (Ser155) and Bcl-XL were from Cell Signalling Technology. An antibody that detected total Bad protein was raised in-house. The Flag antibody was from Sigma and HRP conjugated secondary antibodies were from Pierce (Cheshire, UK) and blots were developed using the enhanced ECL reagent (Amersham, Buckinghamshire, UK).
14-3-3 overlay assays
14-3-3 overlay assays were performed as described . Briefly, proteins from cell extracts or GST pull downs were separated on 4–12% Novex gels (Invitrogen) and transferred to nitrocellulose membrane. Membranes were then treated as for immunoblots. Digoxygenin (DIG)-labelled 14-3-3 proteins were incubated with the membranes in place of the primary antibody, followed by incubation with a secondary anti-DIG horseradish peroxidase antibody. Blots were developed using the enhanced ECL reagent (Amersham, Buckinghamshire, UK).
(proviral integration of MMLV)
(cAMP-dependent protein kinase)
(p90 ribosomal S6 kinase)
(p21 activated protein kinase)
(cAMP-dependent protein kinase inhibitor peptide)
(insulin-like growth factor)
(phorbol 12-myristate 13-acetate)
(human embryonic kidney)
(Dulbecco's modified eagles medium).
We would like to thank the Sequencing Service (School of Life Sciences, University of Dundee) for DNA sequencing. This research was supported by the UK Medical Research Council, Astra-Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck and Co, Merck KGaA and Pfizer.
- Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science. 2002, 298: 1912-1934. 10.1126/science.1075762.View ArticlePubMedGoogle Scholar
- Bachmann M, Moroy T: The serine/threonine kinase Pim-1. Int J Biochem Cell Biol. 2005, 37: 726-730. 10.1016/j.biocel.2004.11.005.View ArticlePubMedGoogle Scholar
- Selten G, Cuypers HT, Berns A: Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas. Embo J. 1985, 4: 1793-1798.PubMed CentralPubMedGoogle Scholar
- Selten G, Cuypers HT, Boelens W, Robanus-Maandag E, Verbeek J, Domen J, van Beveren C, Berns A: The primary structure of the putative oncogene pim-1 shows extensive homology with protein kinases. Cell. 1986, 46: 603-611. 10.1016/0092-8674(86)90886-X.View ArticlePubMedGoogle Scholar
- van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, Berns A: Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell. 1989, 56: 673-682. 10.1016/0092-8674(89)90589-8.View ArticlePubMedGoogle Scholar
- Breuer M, Wientjens E, Verbeek S, Slebos R, Berns A: Carcinogen-induced lymphomagenesis in pim-1 transgenic mice: dose dependence and involvement of myc and ras. Cancer Res. 1991, 51: 958-963.PubMedGoogle Scholar
- Breuer ML, Cuypers HT, Berns A: Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. Embo J. 1989, 8: 743-748.PubMed CentralPubMedGoogle Scholar
- Allen JD, Verhoeven E, Domen J, van der Valk M, Berns A: Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene. 1997, 15: 1133-1141. 10.1038/sj.onc.1201288.View ArticlePubMedGoogle Scholar
- Mochizuki T, Kitanaka C, Noguchi K, Sugiyama A, Kagaya S, Chi S, Asai A, Kuchino Y: Pim-1 kinase stimulates c-Myc-mediated death signaling upstream of caspase-3 (CPP32)-like protease activation. Oncogene. 1997, 15: 1471-1480. 10.1038/sj.onc.1201326.View ArticlePubMedGoogle Scholar
- Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T: Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity. 1999, 11: 709-719. 10.1016/S1074-7613(00)80145-4.View ArticlePubMedGoogle Scholar
- Cuypers HT, Selten G, Berns A, Geurts van Kessel AH: Assignment of the human homologue of Pim-1, a mouse gene implicated in leukemogenesis, to the pter-q12 region of chromosome 6. Hum Genet. 1986, 72: 262-265. 10.1007/BF00291892.View ArticlePubMedGoogle Scholar
- Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A: The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci U S A. 1989, 86: 8857-8861.PubMed CentralView ArticlePubMedGoogle Scholar
- Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature. 2001, 412: 822-826. 10.1038/35090585.View ArticlePubMedGoogle Scholar
- Deneen B, Welford SM, Ho T, Hernandez F, Kurland I, Denny CT: PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins. Mol Cell Biol. 2003, 23: 3897-3908. 10.1128/MCB.23.11.3897-3908.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Fujii C, Nakamoto Y, Lu P, Tsuneyama K, Popivanova BK, Kaneko S, Mukaida N: Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int J Cancer. 2005, 114: 209-218. 10.1002/ijc.20719.View ArticlePubMedGoogle Scholar
- Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, Ryder J, Johnson T, Lilly MB, Kraft AS: Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res. 2003, 23: 167-178.PubMedGoogle Scholar
- Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS: Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta. 2002, 1593: 45-55. 10.1016/S0167-4889(02)00347-6.View ArticlePubMedGoogle Scholar
- Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y: Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem. 1999, 274: 18659-18666. 10.1074/jbc.274.26.18659.View ArticlePubMedGoogle Scholar
- Winn LM, Lei W, Ness SA: Pim-1 phosphorylates the DNA binding domain of c-Myb. Cell Cycle. 2003, 2: 258-262.View ArticlePubMedGoogle Scholar
- Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB: The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 2003, 17: 1841-1854. 10.1101/gad.1105003.PubMed CentralView ArticlePubMedGoogle Scholar
- Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M: The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003, 278: 45358-45367. 10.1074/jbc.M307933200.View ArticlePubMedGoogle Scholar
- Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ: Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004, 571: 43-49. 10.1016/j.febslet.2004.06.050.View ArticlePubMedGoogle Scholar
- Nosaka T, Kitamura T: Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCR-ABL-mediated transformation. Exp Hematol. 2002, 30: 697-702. 10.1016/S0301-472X(02)00808-1.View ArticlePubMedGoogle Scholar
- Lilly M, Kraft A: Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Cancer Res. 1997, 57: 5348-5355.PubMedGoogle Scholar
- Puthalakath H, Strasser A: Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 2002, 9: 505-512. 10.1038/sj.cdd.4400998.View ArticlePubMedGoogle Scholar
- Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997, 91: 231-241. 10.1016/S0092-8674(00)80405-5.View ArticlePubMedGoogle Scholar
- Blume-Jensen P, Janknecht R, Hunter T: The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr Biol. 1998, 8: 779-782. 10.1016/S0960-9822(98)70302-1.View ArticlePubMedGoogle Scholar
- del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997, 278: 687-689. 10.1126/science.278.5338.687.View ArticlePubMedGoogle Scholar
- Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T, Murata Y: Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 2000, 60: 5988-5994.PubMedGoogle Scholar
- Fang X, Yu S, Eder A, Mao M, Bast RCJ, Boyd D, Mills GB: Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene. 1999, 18: 6635-6640. 10.1038/sj.onc.1203076.View ArticlePubMedGoogle Scholar
- Wolf D, Witte V, Laffert B, Blume K, Stromer E, Trapp S, d'Aloja P, Schurmann A, Baur AS: HIV-1 Nef associated PAK and PI3-kinases stimulate Akt-independent Bad-phosphorylation to induce anti-apoptotic signals. Nat Med. 2001, 7: 1217-1224. 10.1038/nm1101-1217.View ArticlePubMedGoogle Scholar
- Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ: p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci U S A. 2001, 98: 9666-9670. 10.1073/pnas.171301998.PubMed CentralView ArticlePubMedGoogle Scholar
- Lizcano JM, Morrice N, Cohen P: Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. Biochem J. 2000, 349: 547-557. 10.1042/0264-6021:3490547.PubMed CentralView ArticlePubMedGoogle Scholar
- Harada H, Becknell B, Wilm M, Mann M, Huang LJ, Taylor SS, Scott JD, Korsmeyer SJ: Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell. 1999, 3: 413-422. 10.1016/S1097-2765(00)80469-4.View ArticlePubMedGoogle Scholar
- Virdee K, Parone PA, Tolkovsky AM: Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contributes to cell survival. Curr Biol. 2000, 10: R883-10.1016/S0960-9822(00)00843-5.View ArticlePubMedGoogle Scholar
- Dramsi S, Scheid MP, Maiti A, Hojabrpour P, Chen X, Schubert K, Goodlett DR, Aebersold R, Duronio V: Identification of a novel phosphorylation site, Ser-170, as a regulator of bad pro-apoptotic activity. J Biol Chem. 2002, 277: 6399-6405. 10.1074/jbc.M109990200.View ArticlePubMedGoogle Scholar
- Konishi Y, Lehtinen M, Donovan N, Bonni A: Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol Cell. 2002, 9: 1005-1016. 10.1016/S1097-2765(02)00524-5.View ArticlePubMedGoogle Scholar
- Masters SC, Yang H, Datta SR, Greenberg ME, Fu H: 14-3-3 inhibits Bad-induced cell death through interaction with serine-136. Mol Pharmacol. 2001, 60: 1325-1331.PubMedGoogle Scholar
- Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996, 87: 619-628. 10.1016/S0092-8674(00)81382-3.View ArticlePubMedGoogle Scholar
- Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB, Greenberg ME: 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell. 2000, 6: 41-51. 10.1016/S1097-2765(00)00006-X.View ArticlePubMedGoogle Scholar
- Tan Y, Demeter MR, Ruan H, Comb MJ: BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem. 2000, 275: 25865-25869. 10.1074/jbc.M004199200.View ArticlePubMedGoogle Scholar
- Wang SW, Denny TA, Steinbrecher UP, Duronio V: Phosphorylation of Bad is not essential for PKB-mediated survival signaling in hemopoietic cells. Apoptosis. 2005, 10: 341-348. 10.1007/s10495-005-0808-4.View ArticlePubMedGoogle Scholar
- Chiang CW, Kanies C, Kim KW, Fang WB, Parkhurst C, Xie M, Henry T, Yang E: Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. Mol Cell Biol. 2003, 23: 6350-6362. 10.1128/MCB.23.18.6350-6362.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J, Berns A: Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol. 2004, 24: 6104-6115. 10.1128/MCB.24.13.6104-6115.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Datta SR, Ranger AM, Lin MZ, Sturgill JF, Ma YC, Cowan CW, Dikkes P, Korsmeyer SJ, Greenberg ME: Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell. 2002, 3: 631-643. 10.1016/S1534-5807(02)00326-X.View ArticlePubMedGoogle Scholar
- Saris CJ, Domen J, Berns A: The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. Embo J. 1991, 10: 655-664.PubMed CentralPubMedGoogle Scholar
- Andersson S, Davis DL, Dahlback H, Jornvall H, Russell DW: Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem. 1989, 264: 8222-8229.PubMedGoogle Scholar
- Sanchez I, Hughes RT, Mayer BJ, Yee K, Woodgett JR, Avruch J, Kyriakis JM, Zon LI: Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature. 1994, 372: 794-798.View ArticlePubMedGoogle Scholar
- McCoy CE, Campbell DG, Deak M, Bloomberg GB, Arthur JS: MSK1 activity is controlled by multiple phosphorylation sites. Biochem J. 2005, 387: 507-517. 10.1042/BJ20041501.PubMed CentralView ArticlePubMedGoogle Scholar
- Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, Arthur JS: MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol. 2002, 22: 2871-2881. 10.1128/MCB.22.8.2871-2881.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Campbell DG, Morrice N: Identification of protein phosphorylation sites by a combination of mass spectrometry and solid phase Edman sequencing. J Biom Tech. 2002, 13: 119-130.Google Scholar
- Moorhead G, MacKintosh C: Affinity methods for phosphorylation-dependent interactions. Methods Mol Biol. 2004, 261: 469-478.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.